Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SILENOR

« Back to Dashboard

Summary for Tradename: SILENOR

Patents:9
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: SILENOR

Clinical Trials for: SILENOR

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Status: Completed Condition: Sleep Initiation and Maintenance Disorders

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Status: Recruiting Condition: Lymphoma; Malignant Mesothelioma; Malignant Pericardial Effusion; Malignant Pleural Effusion; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Soft Tissue Sarcoma; Thymoma and Thymic Carcinoma

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
Status: Recruiting Condition: Acute Oral Mucositis Pain

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Status: Active, not recruiting Condition: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain

Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
Status: Completed Condition: Irritable Bowel Syndrome

The Treatment of Insomnia in Patients With HIV Disease
Status: Completed Condition: HIV Infections; Insomnia

Treatments for Insomnia in Patients With Parkinson's Disease
Status: Recruiting Condition: Parkinson's Disease; Insomnia

YouScript IMPACT Registry
Status: Recruiting Condition: Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Status: Completed Condition: Major Depression

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXYes6,217,909<disabled>Y<disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXYes5,725,884<disabled>Y<disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXYes8,513,299<disabled><disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo6,211,229<disabled><disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo5,866,166<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SILENOR

Drugname Dosage Strength RLD Submissiondate
doxepin hydrochlorideTablets3 mg and 6 mgSilenor9/16/2010

Patent activity for: SILENOR

Expiration due to failure to pay maintenance fee
Patent Number:5,725,884 Tradename:
SILENOR
Expiration Date:March 10, 2006
Patent Number:5,948,438 Tradename:
SILENOR
Expiration Date:September 07, 2011
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc